Shahla Bari
Shahla Bari
Pankti Reid
Pankti Reid
Thomas Chatzikonstantinou
Thomas Chatzikonstantinou
Could bispecific antibodies be used as consolidation treatment after R-CHOP for DLBCL? [0.03%]
双特异性抗体能否用于R-CHOP治疗后的DLBCL巩固治疗？
Matthew A Lunning
Matthew A Lunning
Artificial intelligence in prostate cancer diagnosis and management: state-of-the-art approaches and emerging innovations [0.03%]
前列腺癌诊断和管理中的人工智能技术：前沿方法与新兴创新
Matthew S Lee,Chloe T Shi,Tae-Hee Kim et al.
Matthew S Lee et al.
Artificial intelligence (AI) is rapidly changing the field of medicine, and prostate cancer is no exception. The significant heterogeneity that characterizes the natural history of prostate cancer often leads to under- or overtreatment. Mor...
Highlights in gynecologic cancer from the 2026 American Society of Clinical Oncology Annual Meeting [0.03%]
2026年美国临床肿瘤学会年会妇科肿瘤亮点
Ursula A Matulonis
Ursula A Matulonis
Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report [0.03%]
卡博替尼联合纳武利尤单抗治疗晚期肾细胞癌的临床疗效：一例临床病例报告
Pedro C Barata,Ivan Macharashvili
Pedro C Barata
Deborah M Stephens
Deborah M Stephens